Antimicrobial Resistance (AMR) is one of the most pressing global health threats, undermining our ability to treat infections effectively and placing millions of lives at risk. The recent Global Antibiotic Resistance Surveillance Report 2025, published by the World Health Organization (WHO), confirms a critical and rising resistance trend to life-saving medicines around the world.
This analysis is the most extensive report to date, compiled using data from the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS).
GLASS is a vital global effort to standardize surveillance, helping countries build national systems and generate reliable evidence to guide public health policy. The 2025 report synthesizes data from over 23 million bacteriologically confirmed infections reported by more than 100 countries in 2023.
The Growing Threat to Common Treatments
The GLASS system monitors infections in four key areas of human health: bloodstream infections, urinary tract infections, gastrointestinal infections, and urogenital gonorrhea. The data clearly show that the effectiveness of first-choice treatments for common infections in these areas is severely compromised by rising resistance.
The severity of the challenge is laid bare by the numbers:
A Global Problem with an Uneven Burden
Antibiotic resistance is high everywhere, but its distribution is highly uneven across regions. The burden of AMR disproportionately affects low and middle-income countries and those with weaker health systems. In these regions, limited diagnostic capacity, inadequate infection control, and restricted access to effective drugs create a vicious cycle, leading to higher rates of resistance. Conversely, this global crisis is driving many countries to strengthen their national AMR surveillance systems to better track and combat this growing threat.
On a local level, Türkiye has also acted. The country established the National Antimicrobial Resistance Surveillance System to monitor this threat. National interventions, such as prohibiting over the counter antibiotic sales, have demonstrated that coordinated efforts can lead to a reduction in antibiotic consumption.
The Power of Molecular Diagnostics in a Crisis
To preserve the effectiveness of the few remaining treatment options, the WHO’s priorities for action are clear: scaling up diagnostics for targeted antibiotic therapy is essential to preserve the efficacy of treatment.
When a patient is critically ill, especially with a bloodstream infection, traditional culture methods that take days to produce results are too slow. We need rapid, precise tools to identify not just the infection, but the specific resistance genes present. This molecular approach allows clinicians to immediately prescribe the correct, targeted antibiotic, rather than relying on broad-spectrum drugs that may fail and accelerate resistance.
Anatolia’s Bosphore Solutions for AMR Surveillance
Anatolia is committed to supporting laboratories with the rapid and accurate molecular diagnostics required to combat the global AMR crisis.
To address the urgent threat of antimicrobial resistance highlighted in the GLASS report, we offer a specialized Real–Time PCR portfolio for fast, targeted therapy. Bosphore ABR Screening Kits are multiplex assay that simultaneously detects and identifies critical resistance genes. Additionally, Bosphore Joint Infection Pathogens Kits, Bosphore Sepsis Bundle Kit, and Bosphore Urinary Tract Infection Pathogens Kits, all designed to rapidly identify pathogens and their associated resistance markers, enable timely, life-saving clinical decisions and bolster global surveillance efforts.
